SynthesisBMC cardiovascular disorders2026
Coronary collateral circulation and mortality in ST-elevation myocardial infarction undergoing primary PCI: an updated systematic review and meta-analysis of 18,443 patients.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary collateral circulation may limit myocardial injury during ST-elevation myocardial infarction (STEMI), but the magnitude of this association with mortality in contemporary practice remains unclear. We conducted an updated meta-analysis to reassess the relationship between collateral status and mortality in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
methodsWe searched PubMed, Embase, and Scopus (March 2020–January 2026) to update the meta-analysis by Allahwala et al. Studies comparing mortality between robust versus poor collaterals were included. Random-effects meta-analysis was performed.
resultsTwenty-six studies comprising 18,443 patients were included (19 studies from the original meta-analysis plus 7 new studies). In the primary analysis of 17 studies using standard Rentrop definitions (15,493 patients), robust collaterals were associated with significantly lower mortality (OR 0.52; 95% CI 0.39–0.71; p < 0.0001; I²=38%). This corresponded to an absolute risk reduction of 2.7%. Importantly, the 3 new studies showed attenuated effects (OR 0.88; 95% CI 0.49–1.58) compared to the 14 original studies (OR 0.47; p = 0.06 for subgroup difference). Meta-regression identified higher baseline mortality as a predictor of larger effect sizes (p = 0.038). The certainty of evidence was LOW (GRADE).
conclusionsRobust coronary collaterals are associated with lower mortality in STEMI patients undergoing primary PCI. However, the apparent attenuated association in contemporary studies likely reflects statistical dilution due to lower baseline mortality rather than diminished biological relevance of collaterals. Given the LOW certainty of evidence from observational data, collateral assessment should be considered prognostic rather than a basis for interventions. REVIEW REGISTRATION: (PROSPERO Registration ID: CRD420261278634) CLINICAL TRIAL NUMBER: Not Applicable (As this is a Systematic Review and Meta-Analysis and not a clinical trial).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.